Abstract
Nicotinamide phosphoribosyltransferase (NAMPT), an enzyme taking part in main NAD biosynthetic pathway, is an attractive target for anticancer therapy. The purpose of our study is to find novel NAMPT inhibitors based on in silico drug discovery means including the generation of 3D-QSAR models, and virtual screening techniques. Firstly, ten pharmacophore models were generated by Catalyst/HypoGen algorithm. Hypo1 with high correl value (0.96), large Δcost (77.77), and low root mean square deviation (0.81), featured by four chemical features was selected as the best one. Subsequently, Hypo1 was validated through test set prediction and Fischer’s randomization methodologies. Then we screened some public compound libraries (Asinex, Ibscreen and Natural products database) using Hypo1 for a 3D query. The screened hits were further refined by Lipinski’s rule of five, ADMET properties as well as molecular docking studies. Finally, six molecules with diverse scaffolds exhibited the right pharmacophore features and good binding modes between the receptor and ligands, and were selected as possible candidates against NAMPT for further study.
Keywords: 3D QSAR models, Catalyst/HypoGen, molecular docking, NAMPT, virtual screening.
Combinatorial Chemistry & High Throughput Screening
Title:Discovery of Novel NAMPT Inhibitors Based on Pharmacophore Modeling and Virtual Screening Techniques
Volume: 17 Issue: 10
Author(s): Qianying Yi, Lu Zhou, Xin Shao, Taijin Wang, Guangkai Bao, Huanhuan Shi, Suwen Zhou, Xiaoli Li and Yahui Tian
Affiliation:
Keywords: 3D QSAR models, Catalyst/HypoGen, molecular docking, NAMPT, virtual screening.
Abstract: Nicotinamide phosphoribosyltransferase (NAMPT), an enzyme taking part in main NAD biosynthetic pathway, is an attractive target for anticancer therapy. The purpose of our study is to find novel NAMPT inhibitors based on in silico drug discovery means including the generation of 3D-QSAR models, and virtual screening techniques. Firstly, ten pharmacophore models were generated by Catalyst/HypoGen algorithm. Hypo1 with high correl value (0.96), large Δcost (77.77), and low root mean square deviation (0.81), featured by four chemical features was selected as the best one. Subsequently, Hypo1 was validated through test set prediction and Fischer’s randomization methodologies. Then we screened some public compound libraries (Asinex, Ibscreen and Natural products database) using Hypo1 for a 3D query. The screened hits were further refined by Lipinski’s rule of five, ADMET properties as well as molecular docking studies. Finally, six molecules with diverse scaffolds exhibited the right pharmacophore features and good binding modes between the receptor and ligands, and were selected as possible candidates against NAMPT for further study.
Export Options
About this article
Cite this article as:
Yi Qianying, Zhou Lu, Shao Xin, Wang Taijin, Bao Guangkai, Shi Huanhuan, Zhou Suwen, Li Xiaoli and Tian Yahui, Discovery of Novel NAMPT Inhibitors Based on Pharmacophore Modeling and Virtual Screening Techniques, Combinatorial Chemistry & High Throughput Screening 2014; 17 (10) . https://dx.doi.org/10.2174/1386207317666141121124139
DOI https://dx.doi.org/10.2174/1386207317666141121124139 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Maintenance of Gastrointestinal Glucose Homeostasis by the Gut-Brain Axis
Current Protein & Peptide Science Manipulation of Biliary Lipids by Gene Therapy: Potential Consequences for Patients with Progressive Familial Intrahepatic Cholestasis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Src as a Therapeutic Target in Breast Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Myeloperoxidase as a Target for the Treatment of Inflammatory Syndromes: Mechanisms and Structure Activity Relationships of Inhibitors
Current Medicinal Chemistry A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Current Medicinal Chemistry Vitamin D - Pivotal Nutraceutical in the Regulation of Cancer Metastasis and Angiogenesis
Current Medicinal Chemistry Vitamin D, Pit-1, GH, and PRL: Possible Roles in Breast Cancer Development
Current Medicinal Chemistry Implication of Circadian Rhythms and Melatonin in Major Depressive Disorder: The Evidence Base for New Antidepressant Treatment
Current Psychiatry Reviews A Proteomic Analysis of Human Uterine Myoma
Current Protein & Peptide Science PET Imaging for Gene & Cell Therapy
Current Gene Therapy Interleukin-21 (IL-21) Controls Inflammatory Pathways in the Gut
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Nanostructured Lipid Carriers (NLCs) for Drug Delivery: Role of Liquid Lipid (Oil)
Current Drug Delivery Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Progress in Synthesis and Antitumor Activities of Estradiol-linked Platinum Complex
Mini-Reviews in Medicinal Chemistry The New Immunosuppression: Intervention at the Dendritic Cell-T-Cell Interface
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
Current Medicinal Chemistry Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation
Current Medicinal Chemistry